lemma health
  1. Dupixent

  2. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

Eric L Simpson, Bolanle Akinlade, Marius Ardeleanu

DOI: 10.1056/NEJMc1700366

Comment

•

None participants

•

2017

•

47 citations

Key insights related to Dupixent from this study:

  • What is this paper about?

    Dupilumab is an effective treatment for moderate-to-severe atopic dermatitis in adults and children as young as 6 months. Clinical trials show that 60-70% of patients achieve significant improvement in their eczema symptoms, including reduction in itch and skin clearance.

  • What populations did the authors study?

    Not available patients. With moderate to severe eczema. Patients are 6 months and older. Having taken the following prior treatments: topical treatments and/or systemic treatments.

  • What did the authors find?

    Analyzing metric: EASI-75.
    Findings show: Invervention leads to 60-70%.
    Resulting in: Significantly more patients treated with dupilumab achieved 75% improvement in their eczema compared to placebo.

    Analyzing metric: IGA.
    Findings show: Invervention leads to 35-40%.
    Resulting in: More patients achieved clear or almost clear skin with dupilumab compared to placebo.

  • What conclusions can we draw?

    nan

Did this article interest you?

As a member of the Lemma Health community, you'll stay up to date with research, hear about new products, and get exclusive access to discounts.

By submitting your email, you acknowledge our Terms & Conditions and Privacy Policy

Group of men

Ready for better skin health?

At Lemma Health, we provide evidence-based skin care. Access dermatologists in all 50 states. Appointments available within 3 days. Receive your medications delivered. Get ongoing 24/7/365 support. Coordinate your care across specialties.